For Immediate Release

3D BioFibR Enters the Bioprinting and 3D Cell Culture Market with the Launch of Two CollaFibR™ Tissue Engineering Products

June 26, 2023 – HALIFAX, Nova Scotia - 3DBioFibR, a leading innovator in tissue engineering, announced today it is launching two new collagen fiber products, µCollaFibR™ (pronounced micro-CollaFibR™) and CollaFibR™ 3D scaffold. Made using 3D BioFibR's proprietary and new dry-spinning technology to create collagen fibers at commercial scales, these off-the-shelf products offer significant advantages for tissue engineering and tissue culture applications and are now available for sale, to the scientific and medical communities at www.3DBioFibR.com.

µCollaFibR™ is a bioink additive for use in 3D bioprinting of tissue and organ models in a laboratory setting. µCollaFibR mimics the body's natural cellular scaffold and acts like a biological rebar in bioinks used to print living tissues. When added to bioinks, µCollaFibR improves the mechanical durability of printed tissues so multiple cell types can be assembled layer-by-layer to produce highly functional tissue and organ models.

"3D bioprinting is the future of regenerative medicine and it's exciting to offer µCollaFibR to enhance the capabilities in 3D bioprinting," said Kevin Sullivan, CEO of 3D BioFibR. "We all want to imagine a future where doctors could just print a kidney, using cells from the patient, instead of having to find a donor match. Our collagen fibers represent a significant improvement over existing scaffolds used in 3D bioprinting, moving the field closer to this reality."

The CollaFibR™ scaffold for 3D cell culture allows researchers to study cellular reactions in a more physiologically relevant 3D environment, compared to traditional 2D cultures. The advantage of the CollaFibR scaffold is that it uses GMP type 1 collagen to produce a consistent collagen fiber matrix that resembles the biomechanical and biochemical properties of natural cellular environments.



Sullivan added, "Our CollaFibR scaffold allows cells to grow and interact with the surrounding cellular scaffold in 3D, making it ideal for creating realistic tissue constructs for laboratory testing of new drugs and tissue models. Plus, our standard well plate dimensions are compatible with automated equipment for high throughput compound screening and advanced microscopy."

About Collagen

In the human body, collagen plays a crucial role as the primary structural element of the extracellular matrix. This matrix forms a supportive framework for tissues, holding them together and imparting mechanical durability. Collagen fibers also constitute around 30% of the total protein content in the body. Although collagen has widespread applications in the biomedical field, researchers and clinicians typically utilize digested collagen in its monomeric form (individual proteins). While monomeric collagen serves many valuable functions, there has been a persistent effort, for over five decades, to reassemble these individual proteins into fibers that closely resemble natural collagen fibers found in the body, in terms of appearance, structure, and function.

For Immediate Release

About 3D BioFibR Inc.
3D BioFibR produces high value collagen fibers at commercial scales for a variety of tissue engineering and medical applications. The Company's proprietary dry-spinning process produces fibers that are best-in-class from a strength, diameter, and quality perspective, recreating the natural appearance, structure, and function of collagen fibers. This manufacturing process is at least 3,600x faster than competing manufacturing processes making its collagen fibers accessible for an increasing number of bio-medical applications in the growing tissue engineering market. For more information, visit www.3DBioFibR.com.

##

This news release contains "forward-looking statements," which reflect the current expectations of the Company's management for future growth, results of operations, performance and business prospects. Forward-looking statements involve significant known and unknown risks, uncertainties and assumptions.

INVESTOR RELATIONS
Kevin Sullivan, CEO
3D BioFibR Inc.
E: **Info@3DBioFibR.com**
W: **www.3DBioFibR.com**

MEDIA CONTACT
Jennifer Cameron
Communications Advisor
E: jennifercameronpr@gmail.com
T: 902-209-4704